Basic Information
| LncRNA/CircRNA Name | LINC00973 |
| Synonyms | NA |
| Region | GRCh38_3:98981058-98983096 |
| Ensemble | ENSG00000240476 |
| Refseq |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | 5-fluorouracil, Oxaliplatin, and irinotecan | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | colon cancer |
| ICD-0-3 | C18 |
| Methods | qPCR |
| Sample | colon cancer cell lines(HT-29 and HCT-116) |
| Expression Pattern | up-regulated |
| Function Description | TANRIC data show that LINC00973 low expressiongroups of head and neck, as well as of kidney cancer patients havesignificantly higher survival rate than high expression groups. The most frequent changes were detected for LINC00973, whose content is most strongly and consistently increased upon treatment of both colon cancer cell lines with all three chemotherapeutic drugs(5-fluorouracil, oxaliplatin, and irinotecan). |
| Pubmed ID | 29870803 |
| Year | 2018 |
| Title | Expression of Long Non-Coding RNA LINC00973 Is Consistently Increased Upon Treatment of Colon Cancer Cells With Different Chemotherapeutic Drugs |
External Links
| Links for LINC00973 | GenBank HGNC NONCODE |
| Links for colon cancer | OMIM COSMIC |